The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...

Rami Komrokji, M.D.: Once we establish a diagnosis, our next step is thinking of the risk of a disease, because as you mentioned, those diseases are serious, but the risks vary. Maybe you can tell us ...

Please provide your email address to receive an email when new articles are posted on . Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, that ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Seventy-nine patients (40 with PV and 39 with ET) have ...

Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia Authors: Luciana Teofili, Maurizio Martini, Myriam Luongo, Antonella Di Mario, Giuseppe Leone, Valerio De Stefano, and ...

Preliminary findings from 51 evaluable ET patients showed treatment with INCA033989 monotherapy demonstrated rapid and durable normalization of platelet counts. The Food and Drug Administration (FDA) ...

Enrollment completed with 73 patients in April 2022 Of the 32 patients treated with bomedemstat for more than 24 weeks: 97% (31/32) achieved platelet count reduction to ≤400 x 109/L. 94% (30/32) ...

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or ...

Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver ...

71% (12/17) showed a decrease in Total Symptom Score (TSS). 53% (9/17) showed a ≥50% decrease in TSS. Patients with all genotypes identified in the study (CALR, JAK2 V617F, Triple Negative) responded ...